Radiopharm Theranostics (RADX) shares were nearly 300% higher pre-bell Monday after the company said that RAD 101 achieved the primary endpoint in 92% of patients in a phase 2b trial in brain metastases.
Immunome (IMNM) stock was up 28% after the company said that varegacestat met the primary endpoint and all key secondary endpoints in a phase 3 trial in patients with progressing desmoid tumors.
Biodexa Pharmaceuticals (BDRX) shares were 9% higher, recovering from Friday's losses.
ARB IOT Group (ARBB) stock was up 9%, extending Friday's rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments